FDA OKs subcutaneous version of J&J's Darzalex
May 01, 2020 2:41 PM ETJohnson & Johnson (JNJ), HALO, GMABJNJ, HALO, GMABBy: Douglas W. House, SA News Editor2 Comments
- The FDA approves a subcutaneous formulation of Johnson & Johnson's (JNJ -1.9%) multiple myeloma med Darzalex (daratumumab). Originally, the CD38-directed cytolytic antibody was administered via intravenous infusion.
- The formulation is based on Halozyme's (HALO +0.6%) Enhanze drug delivery technology.
- J&J in-licensed exclusive global rights to the product from Genmab A/S (GMAB +2.6%) in August 2012.